[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].

Yuya Koda, Takehiko Mori, Takayuki Shimizu, Jun Kato, Akiko Yamane, Ken Sadahira, Yuiko Tsukada, Kenji Yokoyama, Norisato Hashimoto, Yutaka Hattori, Shinichiro Okamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We herein report two patients (70- and 45-year-old men) with refractory multiple myeloma who developed paralytic ileus shortly after starting bortezomib therapy. Bortezomib (1.3 mg/m(2)) was given on days 1, 4, 8, and 11 with daily oral solution itraconazole or voriconazole. Twelve and 15 days after beginning the therapy, each patient developed paralytic ileus. Interestingly, no other signs of peripheral neuropathy such as fingertip numbness were observed at the onset of ileus. Sporadic cases of paralytic ileus after bortezomib therapy have been reported, most of which developed ileus after several courses of bortezomib therapy. Our cases developed paralytic ileus shortly after initiating bortezomib, strongly suggesting that autonomic neuropathy due to bortezomib was induced by the concomitant use of itraconazole or voriconazole.

Original languageEnglish
Pages (from-to)760-764
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume53
Issue number8
Publication statusPublished - 2012 Aug

Fingerprint

Intestinal Pseudo-Obstruction
Azoles
Multiple Myeloma
Itraconazole
Ileus
Hypesthesia
Peripheral Nervous System Diseases
Therapeutics
Bortezomib

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{f9c8bcd0166f4429acab9bbd78ffab04,
title = "[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].",
abstract = "We herein report two patients (70- and 45-year-old men) with refractory multiple myeloma who developed paralytic ileus shortly after starting bortezomib therapy. Bortezomib (1.3 mg/m(2)) was given on days 1, 4, 8, and 11 with daily oral solution itraconazole or voriconazole. Twelve and 15 days after beginning the therapy, each patient developed paralytic ileus. Interestingly, no other signs of peripheral neuropathy such as fingertip numbness were observed at the onset of ileus. Sporadic cases of paralytic ileus after bortezomib therapy have been reported, most of which developed ileus after several courses of bortezomib therapy. Our cases developed paralytic ileus shortly after initiating bortezomib, strongly suggesting that autonomic neuropathy due to bortezomib was induced by the concomitant use of itraconazole or voriconazole.",
author = "Yuya Koda and Takehiko Mori and Takayuki Shimizu and Jun Kato and Akiko Yamane and Ken Sadahira and Yuiko Tsukada and Kenji Yokoyama and Norisato Hashimoto and Yutaka Hattori and Shinichiro Okamoto",
year = "2012",
month = "8",
language = "English",
volume = "53",
pages = "760--764",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "8",

}

TY - JOUR

T1 - [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].

AU - Koda, Yuya

AU - Mori, Takehiko

AU - Shimizu, Takayuki

AU - Kato, Jun

AU - Yamane, Akiko

AU - Sadahira, Ken

AU - Tsukada, Yuiko

AU - Yokoyama, Kenji

AU - Hashimoto, Norisato

AU - Hattori, Yutaka

AU - Okamoto, Shinichiro

PY - 2012/8

Y1 - 2012/8

N2 - We herein report two patients (70- and 45-year-old men) with refractory multiple myeloma who developed paralytic ileus shortly after starting bortezomib therapy. Bortezomib (1.3 mg/m(2)) was given on days 1, 4, 8, and 11 with daily oral solution itraconazole or voriconazole. Twelve and 15 days after beginning the therapy, each patient developed paralytic ileus. Interestingly, no other signs of peripheral neuropathy such as fingertip numbness were observed at the onset of ileus. Sporadic cases of paralytic ileus after bortezomib therapy have been reported, most of which developed ileus after several courses of bortezomib therapy. Our cases developed paralytic ileus shortly after initiating bortezomib, strongly suggesting that autonomic neuropathy due to bortezomib was induced by the concomitant use of itraconazole or voriconazole.

AB - We herein report two patients (70- and 45-year-old men) with refractory multiple myeloma who developed paralytic ileus shortly after starting bortezomib therapy. Bortezomib (1.3 mg/m(2)) was given on days 1, 4, 8, and 11 with daily oral solution itraconazole or voriconazole. Twelve and 15 days after beginning the therapy, each patient developed paralytic ileus. Interestingly, no other signs of peripheral neuropathy such as fingertip numbness were observed at the onset of ileus. Sporadic cases of paralytic ileus after bortezomib therapy have been reported, most of which developed ileus after several courses of bortezomib therapy. Our cases developed paralytic ileus shortly after initiating bortezomib, strongly suggesting that autonomic neuropathy due to bortezomib was induced by the concomitant use of itraconazole or voriconazole.

UR - http://www.scopus.com/inward/record.url?scp=84874440128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874440128&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 760

EP - 764

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 8

ER -